Nanopath Inc
StreetZero Signal 81
About Nanopath Inc
Nanopath Inc. is a Cambridge, Massachusetts-based molecular diagnostics company focused on point-of-care testing for women's health. It develops a biosensing platform enabling high-quality molecular testing in minutes, including a 15-minute vaginitis assay. The company was founded in 2019 and operates as a privately held B2B biotechnology business.
LATEST FUNDINGPrivate Placement
$29.9M
Announced 2026-11-13
TOTAL RAISED$29.9M
IN THE NEWS
- 🔗 Nanopath Raises $25M to Advance 15-Minute Vaginitis Diagnostic Test
- 🔗 Nanopath Secures $10 Million in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women's Health
- 🔗 Nanopath Secures $10 Million in Series A Funding to Develop and Commercialize Point-of-Care Diagnostics for Women's Health - SV Health Investors
- 🔗 Nanopath
- 🔗 Nanopath 2026 Company Profile: Valuation, Funding & Investors | PitchBook
EMPLOYEES—
FOUNDED2019
HQCambridge, MA, United States
Industry
Biotechnology
Tags
B2BBiotechnologyDiagnosticsWomen's Health
Investors
Key highlights
- Raised $10M Series A in 2022 and $25M Series B to advance point-of-care molecular diagnostics.
- Platform enables 15-minute vaginitis testing without amplification.
- Backed by Norwest Venture Partners, SV Health Investors, and multiple non-dilutive grants.
- Preparing for FDA 510(k) clinical study and commercial launch.
- Total funding reaches $29.9M across equity and grants.
Tech stack
Nanotechnology-based biosensingOptical biosensingAmplification-free molecular detectionMultiplexed pathogen detectionMicrofluidics
Ask StreetZero about Nanopath Inc
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account